Two of these differentially expressed antigens (KP-OVA-38/C10orf62 and KP-OVA-52/C15orf60) are novel gene products, and the remaining tissue-restricted antigen (KP-OVA-35/TNP1) has not been previously studied in relation to cancer. Here, REC114 is linked to cancer.